Stacy Enxing Seng Joins the Vesper Medical Board of Directors
WAYNE, Pa.--(BUSINESS WIRE)--Vesper Medical, Inc., a developer of medical devices for deep venous disease, today announced that Stacy Enxing Seng has joined the board of directors effective immediately.
An accomplished executive leader, Stacy has over 25 years in sales, marketing and operational leadership roles building innovative technology portfolios, demonstrated clinical outcomes, exceptional management teams and world-class company cultures. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. She currently serves as a venture partner for Lightstone Ventures and since 2013 has also focused her work on engaging as a professional director, serving as an Independent Director and committee member for both public and venture-backed private companies. In addition to serving on the Vesper Medical board, Stacy currently serves a non-executive Independent Director for Hill-Rom Holdings, Inc (NYSE: HRC), Sonova Holding AG (VTX: SOON), and LivaNova, Inc (NASDAQ: LIVN). She also serves as Chairwoman of the Board for CALA Health, Contego and Independent Director for PreCARDIA, as well as a Director for the Fogary Institute, a non-profit educational innovator.
“I am thrilled to join the Vesper board of directors. I have long had a passion for the importance of specifically designed and studied technology for peripheral vascular disease treatment,” stated Stacy Enxing Seng. “The Duo Venous Stent system and the VIVID Trial are clearly designed with the improvement of deep venous disease treatment in mind. I look forward to supporting Bruce and his team, as well as the Vesper Investors, to bring this important technology to the market.”
Over the course of her career, Stacy has been involved in the launch of over 20 medtech technologies, more than 10 substantive M&A transactions and served as the President of Covidien’s Vascular Therapies business following its acquisition of ev3, a medical technology start-up she co-created. Ms. Enxing Seng received a B.A. in Public Policy from Michigan State University and M.B.A. from Harvard University.
“Stacy brings a wealth of experience to our board of directors,” said Bruce Shook, Vesper Medical President and CEO. “Few executives in our industry can match her breadth and depth across large companies, entrepreneurial ventures and private equity investment. When you add to that her experience in the development of venous therapies, she is an ideal fit for Vesper Medical.”
About the Vesper Duo Venous Stent System
The Vesper DUO Venous Stent System® is a next generation venous technology that advances the treatment of deep venous disease. Vesper Medical’s portfolio approach enables the clinician to tailor treatment in the iliofemoral venous anatomy based on disease patterns and severity. The DUO-HYBRID™ stent has a distinct integrated design that changes along its length from high crush resistance in the iliac region to high flexibility in the pelvic region, thus targeting the dynamic loading conditions in the iliofemoral venous system. The DUO-EXTEND™ stent is engineered to smoothly integrate with the DUO-HYBRID stent to provide physicians the flexibility to treat longer lesions.
Visit http://www.vespermedical.com for more information.
About Vesper Medical
Vesper Medical is a privately held medical device company that develops minimally-invasive peripheral vascular products, with a focus on advancing and improving the treatment of deep venous disease. Visit www.vespermedical.com for more information.
This press release contains “forward-looking statements” concerning the development of Vesper Medical's products, the potential benefits and attributes of such products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Vesper Medical undertakes no obligation to update any forward-looking statements for any reason.
Vesper DUO Venous Stent System®, Vesper DUO EXTEND Venous Stent System™, DUO-HYBRID™ and DUO-EXTEND™ are trademarks of Vesper Medical, Inc.
CAUTION: Investigational device. Limited by Federal (United States) law to investigational use.